Assessing efficacy and safety of genome EDITing approaches for Sickle Cell Disease

Informations projet

EDITSCD

N° de convention de subvention: 101057659

DOI 10.3030/101057659

Date de signature de la CE 24 Mai 2022

Date de début 1 Septembre 2022

Date de fin 31 Août 2027

Financé au titre de

• Health

Coût total € 6 532 000,00

Contribution de l’UE € 6 532 000,00

Coordonné par

IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION
France

Livrables

Documents, reports (2)

Data Management Plan 2

We will revise the data management plan (see paragraph 1.2.6) at month 18

Data Management Plan 1

A document describing the data management plan (see paragraph 1.2.6) will be produced and provided at month 6

Websites, patent fillings, videos etc. (1)

Project website and logo

A web page will be created in English for information of patients, families, patient organizations, the general public, health care providers, financial actors on the aims and progress of the project.

Publications

Peer reviewed articles (1)

Clinical genome editing to treat sickle cell disease—A brief update

Auteurs: Parinaz Zarghamian; Julia Klermund; Toni Cathomen
Publié dans: Crossref, 2023, ISSN 2296-858X
Éditeur: Frontiers in Medecine
DOI: 10.3389/fmed.2022.1065377